21 related articles for article (PubMed ID: 10386714)
1. Post-chemoradiation volumetric response predicts survival in newly diagnosed glioblastoma treated with radiation, temozolomide, and bevacizumab or placebo.
Ellingson BM; Abrey LE; Garcia J; Chinot O; Wick W; Saran F; Nishikawa R; Henriksson R; Mason WP; Harris RJ; Leu K; Woodworth DC; Mehta A; Raymond C; Chakhoyan A; Pope WB; Cloughesy TF
Neuro Oncol; 2018 Oct; 20(11):1525-1535. PubMed ID: 29897562
[TBL] [Abstract][Full Text] [Related]
2. Evidence and context of use for contrast enhancement as a surrogate of disease burden and treatment response in malignant glioma.
Ellingson BM; Wen PY; Cloughesy TF
Neuro Oncol; 2018 Mar; 20(4):457-471. PubMed ID: 29040703
[TBL] [Abstract][Full Text] [Related]
3. Modified Criteria for Radiographic Response Assessment in Glioblastoma Clinical Trials.
Ellingson BM; Wen PY; Cloughesy TF
Neurotherapeutics; 2017 Apr; 14(2):307-320. PubMed ID: 28108885
[TBL] [Abstract][Full Text] [Related]
4. Prospective single-arm study of 72 Gy hyperfractionated radiation therapy and combination chemotherapy for anaplastic astrocytomas.
Nomiya T; Nemoto K; Kumabe T; Takai Y; Yamada S
BMC Cancer; 2008 Jan; 8():11. PubMed ID: 18199339
[TBL] [Abstract][Full Text] [Related]
5. Multivariate analysis of clinical prognostic factors in patients with glioblastoma multiforme treated with a combined modality approach.
Jeremic B; Milicic B; Grujicic D; Dagovic A; Aleksandrovic J
J Cancer Res Clin Oncol; 2003 Aug; 129(8):477-84. PubMed ID: 12884028
[TBL] [Abstract][Full Text] [Related]
6. Pharmacotherapy of malignant astrocytomas of children and adults: current strategies and future trends.
Jennings MT; Iyengar S
CNS Drugs; 2001; 15(9):719-43. PubMed ID: 11580310
[TBL] [Abstract][Full Text] [Related]
7. Pre-irradiation carboplatin and etoposide and accelerated hyperfractionated radiation therapy in patients with high-grade astrocytomas: a phase II study.
Jeremic B; Shibamoto Y; Grujicic D; Milicic B; Stojanovic M; Nikolic N; Dagovic A; Aleksandrovic J
Radiother Oncol; 1999 Apr; 51(1):27-33. PubMed ID: 10386714
[TBL] [Abstract][Full Text] [Related]
8. Concurrent accelerated hyperfractionated radiation therapy and carboplatin/etoposide in patients with malignant glioma: long-term results of a phase II study.
Jeremic B; Shibamoto Y; Grujicic D; Stojanovic M; Milicic B; Nikolic N; Dagovic A; Aleksandrovic J
J Neurooncol; 2001 Jan; 51(2):133-41. PubMed ID: 11386410
[TBL] [Abstract][Full Text] [Related]
9. Preirradiation ifosfamide, carboplatin, and etoposide for the treatment of anaplastic astrocytomas and glioblastoma multiforme: a phase II study.
López-Aguilar E; Sepúlveda-Vildósola AC; Rivera-Márquez H; Cerecedo-Díaz F; Hernández-Contreras I; Ramón-García G; Diegopérez-Ramírez J; Santacruz-Castillo E
Arch Med Res; 2000; 31(2):186-90. PubMed ID: 10880725
[TBL] [Abstract][Full Text] [Related]
10. Hyperfractionated radiation therapy and concurrent low-dose, daily carboplatin/etoposide with or without weekend carboplatin/etoposide chemotherapy in stage III non-small-cell lung cancer: a randomized trial.
Jeremic B; Shibamoto Y; Acimovic L; Milicic B; Milisavljevic S; Nikolic N; Dagovic A; Aleksandrovic J; Radosavljevic-Asic G
Int J Radiat Oncol Biol Phys; 2001 May; 50(1):19-25. PubMed ID: 11316542
[TBL] [Abstract][Full Text] [Related]
11. Phase II trial of carmustine, cisplatin, and oral etoposide chemotherapy before radiotherapy for grade 3 astrocytoma (anaplastic astrocytoma): results of North Central Cancer Treatment Group trial 98-72-51.
Rao RD; Krishnan S; Fitch TR; Schomberg PJ; Dinapoli RP; Nordstrom K; Scheithauer B; O'Fallon JR; Maurer MJ; Buckner JC
Int J Radiat Oncol Biol Phys; 2005 Feb; 61(2):380-6. PubMed ID: 15667956
[TBL] [Abstract][Full Text] [Related]
12. Hyperfractionated radiation therapy (HFX RT) followed by multiagent chemotherapy (CHT) in patients with malignant glioma: a phase II study.
Jeremic B; Grujicic D; Antunovic V; Djuric L; Stojanovic M; Shibamoto Y
Int J Radiat Oncol Biol Phys; 1994 Dec; 30(5):1179-85. PubMed ID: 7961028
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
